Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results
StockNews.AI · 11 hours
High Materiality9/10
Information
Full-year 2025 net product revenues of $689 million SYFOVRE® (pegcetacoplan injection) full year 2025 net product revenue of $587 millionEMPAVELI® (pegcetacoplan) full year 2025 net product revenue of $102
Original sourceAI Summary
Apellis Pharmaceuticals reported net product revenues of $689 million for 2025, with significant contributions from SYFOVRE and EMPAVELI. The company is set to advance its product pipeline and has sufficient cash reserves to support its operations toward profitability, making it a strong player in complement biology.
Sentiment Rationale
APLS's solid revenue growth and operational updates align with positive investor sentiment, indicating robust future potential. A recent track record of overcoming previous losses supports confidence in continued recovery.
Trading Thesis
Invest in APLS for potential upside as strong revenue growth supports profitability trajectory.
Market-Moving
- Projected SYFOVRE revenue of $587 million boosts company valuation.
- Successful EMPAVELI launch indicates strong market acceptance and growth potential.
- Upcoming regulatory submission for SYFOVRE may enhance product accessibility.
- Cash reserves exceeding $466 million provide operational stability and growth funding.
Key Facts
- APLS reported $689 million in 2025 net product revenues.
- SYFOVRE generated $587 million, EMPAVELI contributed $102 million.
- Regulatory submission for SYFOVRE's prefilled syringe planned by mid-2026.
- EMPAVELI shows strong launch momentum with ongoing pivotal trials.
- Company has $466 million in cash to support operations toward profitability.
Companies Mentioned
- Sobi (SOBI): Received approval for Aspaveli, resulting in a $25 million milestone payment to APLS.
Corporate Developments
This article falls under Corporate Developments as it highlights APLS's financial performance and strategic milestones that outline its pathway towards sustained revenue growth and profitability, essential for investor confidence and stock performance.